Abstract Clinical heterogeneity in schizophrenia complicates treatment optimization and contributes to substantial variability in antipsychotic response. Symptom-based stratification may help to identify more homogeneous patient groups and improve prediction of treatment outcomes. However, evidence from large longitudinal studies remain limited. Metabolic abnormalities are also highly prevalent in schizophrenia and may contribute to differential treatment response across clinical subgroups.
